Cancer related safety with SGLT2-i and GLP1-RAs: Should we worry?

Gallo, M; Monami, M; Ragni, A; Renzelli, V

Gallo, M; Monami, M; Ragni, A; Renzelli, V.

Afiliación

Gallo M; Endocrinology and Metabolic Diseases Unit, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. Electronic address: marco.gallo@ospedale.al.it.
Monami M; Diabetology, Careggi Hospital and University of Florence, Italy.
Ragni A; Endocrinology and Metabolic Diseases Unit, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Renzelli V; Diabetologist and Endocrinologist, Italian Association of Clinical Diabetologists, Rome, Italy.

Diabetes Res Clin Pract ; 198: 110624, 2023 04.

Article en En | MEDLINE | ID: mdl-36906235

Asunto(s)

Diabetes Mellitus Tipo 2; Neoplasias; Humanos; Transportador 2 de Sodio-Glucosa; Hipoglucemiantes/efectos adversos; Diabetes Mellitus Tipo 2/tratamiento farmacológico; Receptor del Péptido 1 Similar al Glucagón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Neoplasias Límite: Humans Idioma: En Revista: Diabetes Res Clin Pract Asunto de la revista: ENDOCRINOLOGIA Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google